Mycenax Biotech Inc (4726) Fair Value & Analysis
Healthcare · TW · Market cap 5.2B TWD
Fair value as of: Jun 24, 2026
Analysis
Mycenax Biotech Inc (4726) currently trades at 24.50 TWD, while our model-based Fair Value estimate is 34.75 TWD — implying the stock looks roughly 41.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Mycenax Biotech Inc (4726) undervalued?
What is the fair value of 4726?
What is the quality score of 4726?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.